Regeneron Pharmaceuticals (REGN) is set to announce its Q3 2025 earnings on Oct. 28, with analysts predicting a profit of $7.80 per share, down 33.5% from last year. Despite this decline, the company has beaten estimates in three of the last four quarters. REGN’s stock has dropped 44.9% over the past year.

After a strong Q2 earnings release, REGN saw a 2.5% surge in shares. Revenue improved by 3.6% year-over-year to $3.7 billion, exceeding analyst expectations by 10.2%. Adjusted EPS came in at $12.89, up 11.5% from the previous year. Wall Street analysts hold a “Moderate Buy” rating on REGN.

For fiscal 2025, analysts expect REGN to report a profit of $32.36 per share, down 16.2% from last year. Looking ahead to fiscal 2026, EPS is expected to decline by 2.4% year-over-year to $31.57. Despite recent declines in stock value, analysts remain moderately optimistic about REGN’s future performance.

Read more at Yahoo Finance: Regeneron’s Q3 2025 Earnings: What to Expect